
Coya Therapeutics Updates Enrollment in Phase 1 FTD Study
Coya Therapeutics, Inc. (NASDAQ: COYA), a clinical-stage biotech company, announced that five of eight patients have been enrolled in an investigator-initiated academic study of the LD IL-2 + CTLA4-Ig combination for treating Frontotemporal Dementia (FTD). The study is led by…











